In this context, the PI3K/mTOR pathway has emerged as a central regulator of the tumour microenvironment (TME) and recent investigations have unveiled its potential contribution to ICB‐resistance in some epithelial tumour types, such as breast and colorectal cancer.8 Here, MTOR is linked to neoplasm.